Phantom Neuro

Phantom Neuro operates at the intersection of neurotechnology, prosthetics, rehabilitation robotics, and medical devices. Its stated focus is a minimally invasive muscle-machine interface that can control robotic limbs and exoskeletons without brain surgery, positioning the company differently from fully implanted brain-computer-interface approaches. The Phantom X product is described as a system for translating signals from the human body into control of prosthetic or robotic devices in real-world environments. Ottobock is a particularly relevant adjacent player: it led Phantom Neuro’s $19 million Series A and joined the board, making it a strategic ecosystem participant as well as a potential distribution, clinical, or product-development influence. Phantom Neuro’s differentiation is therefore less about scale or commercial reach and more about its minimally invasive architecture, focus on muscle-derived control signals, and effort to combine neuroscience, robotics, precision engineering, and user input from amputees. Clinical-study approval in April 2026 represents an important test of whether those technical claims translate into repeatable patient outcomes.

Phantom Neuro’s trajectory shows a progression from early technical development to increasingly substantial financing and clinical execution. The company was founded in 2020 and raised two Seed rounds in 2022 totaling $9.26 million, led by LionBird and TIME BioVentures. It later received $300,000 in grant funding in January 2025 and reported non-equity assistance from Intel Ignite in April 2024. The major inflection point was the $19 million Series A announced on Apr 15, 2025, bringing total recorded funding to $28.56 million across five rounds and adding Ottobock as both lead investor and board participant. Product communications then emphasized a minimally invasive interface and the Phantom X prosthetic control system. In November 2025, the patient registry created a channel for recruiting amputees and building clinical participation. Approval for a first-in-human study and muscle-machine interface trial in April 2026 marks the clearest shift from laboratory and prototype work toward evidence generation. Public hiring data is limited, although the company is categorized within the 11-to-50 employee range. The next growth phase will depend on clinical execution, regulatory progress, and converting strategic support into repeatable deployment.